Valeant Pharmaceuticals Announces 2015 Annual Meeting Results

LAVAL, Quebec, May 19, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of eleven directors nominated at its 2015 annual meeting of shareholders today.  The detailed results of the vote for the election of directors are set out below: 

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2016 annual meeting of shareholders.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology  and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:Laurie W. Little 949-461-6002 [email protected]

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-2015-annual-meeting-results-300085929.html

SOURCE Valeant Pharmaceuticals International, Inc.